TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...
Multiple Sclerosis News Today4d
ECTRIMS 2024: MS relapse rates fall with 5 years on Briumvi
Five years of continuous Briumvi kept MS relapse rates and disability progression low, according to analyses from a trial's ...
Hosted on MSN5d
IBD 50's TG Therapeutics Rises On Five-Year Data For Multiple Sclerosis Drug
TG Therapeutics stock rose Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...
The Pharma Letter4d
Strong new data for Briumvi in MS
TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b Study - Quick Facts
TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...
The Bakersfield Californian6d
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing ...
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...
Evaluating TG Therapeutics: Insights From 4 Financial Analysts
During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...